UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000041244
Receipt number R000046811
Scientific Title A randomized controlled trial comparing conventional ESD versus hybrid ESD for gastric neoplasms
Date of disclosure of the study information 2020/07/29
Last modified on 2024/04/03 08:22:13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A randomized controlled trial comparing conventional ESD versus hybrid ESD for gastric neoplasms

Acronym

Hybrid-G study

Scientific Title

A randomized controlled trial comparing conventional ESD versus hybrid ESD for gastric neoplasms

Scientific Title:Acronym

A randomized controlled trial comparing conventional ESD versus hybrid ESD for gastric neoplasms

Region

Japan


Condition

Condition

Gastric neoplasm

Classification by specialty

Gastroenterology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

This study investigates the usefulness of snaring during dissection in ESD for gastric neoplasms.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Procedure time of ESD

Key secondary outcomes

Time and speed of mucosal incision
Time and speed of submucosal dissection with or without snaring
En bloc and complete resection
Curability judged by histological assessment of resected specimen
Endoscopic procedural adverse events including intraoperative perforation, delayed perforation and delayed bleeding
Degree of dissected submucosal layer before snaring
Volume of injective solution
Number and time of hemostasis using hemostatic device during procedure
Thickness of submucosal layer in resected specimen
The relationship between outcomes and morphology / location / size/ ulceration / operator's experience.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

When assigned to the standard treatment group (group A), conventional ESD is performed.

Interventions/Control_2

When assigned to the study treatment group (group B), hybrid ESD is performed.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

-Male or female aged 20 years with early gastric neoplasm who will undergo endoscopic resection as a local treatment
-Eligible lesion is diagnosed as a gastric adenoma or adenocarcinoma by endoscopic biopsy within 90 days before enrollment.
-Eligible lesion is endoscopically diagnosed as a mucosal lesion within 20 mm in diameter without ulceration.
-Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of each eligible patient is 0, 1, or 2.
-Eligible patients will be asked to listen to oral explanation and read explanatory documents providing doctors' instruction and sign consent forms. Informed consent will be obtained from each eligible patient before enrollment in the trial
-Stated willingness to comply with all study procedures and availability for the duration of the study

Key exclusion criteria

-Patients with a history of gastric surgery
-Patients on dialysis
-Patients requiring continuous administration of heparin during perioperative period.
-Contraindication with endoscopy; ileus, gastrointestinal perforation or severe respiratory/cardiac disease.
-Metal allergy
-Patients who are judged inappropriate by physician participating in this trial
-Patients who cannot obtain informed consent

Target sample size

82


Research contact person

Name of lead principal investigator

1st name Haruei
Middle name
Last name Ogino

Organization

Graduate School of Medicine, Kyushu University

Division name

Department of Medicine and Bioregulatory Science

Zip code

812-8582

Address

3-1-1, Maidashi, Higashi-ku, Fukuoka

TEL

092-642-5286

Email

ogino@intmed3.med.kyushu-u.ac.jp


Public contact

Name of contact person

1st name Mitsuru
Middle name
Last name Esaki

Organization

Graduate School of Medicine, Kyushu University

Division name

Department of Medicine and Bioregulatory Science

Zip code

812-8582

Address

3-1-1, Maidashi, Higashi-ku, Fukuoka

TEL

092-642-5286

Homepage URL


Email

esaki_saiseikai@yahoo.co.jp


Sponsor or person

Institute

Graduate School of Medicine, Kyushu University

Institute

Department

Personal name



Funding Source

Organization

Graduate School of Medicine, Kyushu University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kyushu University Institutional Review Board for Clinical Trials

Address

3-1-1, Maidashi, Higashi-ku, Fukuoka

Tel

092-642-5082

Email

byskenkyu@jimu.kyushu-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

九州大学病院(福岡県)、九州医療センター(福岡県)、福岡東医療センター(福岡県)、原三信病院(福岡県)、福岡市民病院(福岡県)、済生会二日市病院(福岡県)、福岡中央病院(福岡県)、済生会八幡病院(福岡県)、別府医療センター(大分県)


Other administrative information

Date of disclosure of the study information

2020 Year 07 Month 29 Day


Related information

URL releasing protocol

https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06099-x

Publication of results

Published


Result

URL related to results and publications

https://www.cghjournal.org/article/S1542-3565(22)01019-9/fulltext

Number of participants that the trial has enrolled

82

Results

The procedure time of H-ESD was significantly shorter than that of C-ESD (33.16 min vs 62.46 min; H-ESD/C-ESD ratio: 0.53; 95% confidence interval, 0.41-0.69; P < .0001).

Results date posted

2024 Year 04 Month 03 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Thare was no significant difference between two groups.

Participant flow

A total of 39 and 40 patients underwent H-ESD and C-ESD, respectively.

Adverse events

No difference was observed between the 2 groups.

Outcome measures

The procedure time of H-ESD was significantly shorter than that of C-ESD (33.16 min vs 62.46 min; H-ESD/C-ESD ratio: 0.53; 95% confidence interval, 0.41-0.69; P < .0001). There was no significant difference in mucosal incision time between the 2 groups; the time and speed of submucosal dissection of H-ESD were significantly shorter than those of C-ESD. No difference was observed between the 2 groups in other outcomes.

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2020 Year 07 Month 28 Day

Date of IRB

2020 Year 07 Month 28 Day

Anticipated trial start date

2020 Year 08 Month 01 Day

Last follow-up date

2022 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete

2021 Year 08 Month 27 Day

Date analysis concluded



Other

Other related information



Management information

Registered date

2020 Year 07 Month 29 Day

Last modified on

2024 Year 04 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046811


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name